Bio-Techne (NASDAQ: TECH) reported Q3 EPS of $1.21, $0.07 better than the analyst estimate of $1.14. Revenue for the quarter came in at $163.97 million versus the consensus estimate of $163.97 million.

Third Quarter FY2018 Snapshot

• Third quarter organic revenue increased by 7% (14% reported) to $164.0 million. Year-to-date organic revenues have increased by 9%.
• GAAP EPS was $0.52 vs. $0.59 one year ago. Delivered a record adjusted earnings per share (EPS) of $1.21, an increase of 25% over the prior year.
• Adjusted Operating Margin was 38.1% for the quarter, up 80 basis points over the prior year.
• Acquired Atlanta Biologicals whose products focus on supplying cell culture sera, media and reagents for the life science research market.

For earnings history and earnings-related data on Bio-Techne (TECH) click here.